INTRODUCTION:

The advent of personalized medicine marks a significant and transformative development in the field of modern healthcare. Unlike conventional medical models that rely on generalized treatment protocols, personalized medicine aims to tailor medical interventions to the unique biological makeup of each individual. This approach considers not only clinical parameters but also genetic, environmental, and lifestyle factors that influence disease progression and treatment response¹. At the core of personalized medicine lies the discipline of pharmacogenomics, which investigates how genetic variations affect an individual's response to pharmaceutical agents. These genetic differences particularly those involving drug-metabolizing enzymes (e.g., cytochrome P450 family), transport proteins, and drug targets such as receptors play a crucial role in determining drug efficacy, optimal dosage, and the risk of adverse drug reactions (ADRs).

Incorporating pharmacogenomic insights into clinical decision-making allows healthcare providers to predict which medications are most likely to be effective or harmful for a given patient. This not only enhances therapeutic outcomes and patient safety but also reduces the reliance on trial-and-error prescribing, thereby decreasing healthcare costs and improving resource utilization.

As genomic technologies become more accessible and pharmacogenomic data is increasingly integrated into electronic health records and clinical workflows, personalized medicine is poised to become a cornerstone of future healthcare systems. This review explores the essential concepts, clinical relevance, implementation strategies, and future directions of pharmacogenomics within the broader context of precision medicine^2,3.

Genetic Variation and Drug Response:

Genetic variation is a fundamental determinant of how individuals respond differently to medications. While standard drug therapies may be effective for the majority, a significant portion of patients experience suboptimal outcomes due to genetic differences that impact drug absorption, distribution, metabolism, and elimination, as well as the interaction with molecular targets. Understanding these variations enables clinicians to predict responses more accurately and avoid adverse reactions⁴.

Genetic Polymorphisms:

Genetic polymorphisms are naturally occurring variations in DNA sequences that are present in more than 1% of the population. When these polymorphisms affect genes involved in pharmacokinetics (what the body does to the drug) and pharmacodynamics (what the drug does to the body), they can significantly influence drug response ⁵.

Types of Genetic Polymorphisms Relevant to Drug Response:

· Single Nucleotide Polymorphisms (SNPs): These are the most common form of genetic variation, involving the substitution of a single nucleotide base in the DNA sequence. SNPs can alter the activity or expression of enzymes, transporters, and receptors, thereby impacting drug metabolism and efficacy.

· Insertions and Deletions (Indels): These involve the addition or deletion of small DNA segments, which may shift the genetic reading frame or disrupt protein function, potentially resulting in non-functional or hyper functional proteins.

· Copy Number Variations (CNVs): CNVs involve large segments of DNA that are duplicated or deleted, leading to altered gene dosage. For example, duplication of the CYP2D6 gene can result in ultra-rapid metabolism of certain medications, reducing their therapeutic effect^6,7.

Impact of Genetic Polymorphisms:

1. Altered Drug Metabolism:

o Polymorphisms in metabolizing enzymes such as the cytochrome P450 (CYP450) family produce varied metabolic phenotypes:

§ Poor metabolizers (PM): Enzyme activity is significantly reduced or absent, leading to drug accumulation and potential toxicity.

§ Intermediate metabolizers (IM): Moderate reduction in enzyme activity may necessitate dose adjustments.

§ Extensive metabolizers (EM): Represent the normal metabolic baseline; typically respond well to standard dosing.

§ Ultra-rapid metabolizers (UM): Enhanced enzyme activity may result in sub therapeutic drug levels due to rapid clearance⁸.

2. Modified Drug Transport:

o Genetic variants in transport proteins, such as SLCO1B1, influence the uptake and distribution of drugs, particularly statins. Variants can reduce transport efficiency, increasing drug concentrations and the risk of toxicity⁹.

3. Altered Drug Targets:

o Polymorphisms in drug target genes, including receptors and enzymes, can diminish drug binding affinity or change signalling pathways, affecting pharmacodynamics outcomes. For example, variations in VKORC1 influence sensitivity to warfarin, requiring careful dose management.

Understanding and identifying these polymorphisms through pharmacogenomic testing provide the foundation for precision medicine, allowing clinicians to customize therapies that are both safe and effective for individual patients¹⁰.

Pharmacogenes:

Pharmacogenes are genes that play a pivotal role in determining an individual's response to pharmacological treatments by influencing drug metabolism, transport, and interaction with molecular targets. Inherited genetic polymorphisms in these genes can significantly affect the pharmacokinetics and pharmacodynamics of various medications. By identifying these genes and understanding their variations, clinicians can better anticipate a patient's drug response and customize treatment strategies accordingly¹¹.

Key Examples of Clinically Relevant Pharmacogenes:

1. CYP2D6 (Cytochrome P450 2D6):

· Function: Responsible for the metabolism of approximately 25% of commonly prescribed drugs, including antidepressants, antipsychotics, opioids (e.g., codeine), and beta-blockers.

· Genetic Variability: Over 100 known alleles with wide variability across populations.

· Phenotypes:

o Poor metabolizers: High risk of drug toxicity due to impaired metabolism.

o Ultra-rapid metabolizers: Potential therapeutic failure due to accelerated drug clearance.

· Clinical Example: Codeine is converted into morphine by CYP2D6. Poor metabolizers may not experience pain relief, while ultra-rapid metabolizers may suffer from morphine overdose and respiratory depression ¹².

2. CYP2C9 and VKORC1 (Warfarin Metabolism and Response)

· CYP2C9: Metabolizes S-warfarin, the more active enantiomer. Variants 2 and 3 significantly reduce enzyme function, increasing the risk of haemorrhage.

· VKORC1: Encodes the target enzyme of warfarin, vitamin K epoxide reductase. The -1639G>A variant affects warfarin sensitivity.

· Clinical Implication: Genotype-guided dosing reduces the risk of bleeding or thrombosis in patients undergoing anticoagulation therapy¹³.

3. CYP2C19

· Function: Involved in the metabolism of drugs like clopidogrel, proton pump inhibitors, and some antidepressants.

· Phenotypes:

o Poor metabolizers: Reduced conversion of prodrugs like clopidogrel into their active forms, risking therapeutic failure.

o Ultra-rapid metabolizers: Potentially inadequate drug exposure with standard dosing.

· Clinical Example: In cardiovascular patients, poor CYP2C19 metabolizers receiving clopidogrel are at greater risk of major adverse cardiac events¹⁴.

4. TPMT (Thiopurine S-Methyltransferase)

· Function: Metabolizes thiopurine drugs including azathioprine, 6-mercaptopurine, and thioguanine.

· Variants: Deficiency in TPMT activity can cause excessive accumulation of cytotoxic metabolites.

· Clinical Relevance: Patients with low or absent TPMT activity are at risk of severe bone marrow suppression and should receive significantly lower doses¹⁵.

5. SLCO1B1 (Solute Carrier Organic Anion Transporter Family Member 1B1)

· Function: Encodes a hepatic transporter that facilitates the uptake of statins into the liver.

· Variant: The SLCO1B15 (521T>C) allele is associated with impaired transport and increased risk of statin-induced myopathy, especially with simvastatin.

· Clinical Use: Genetic screening can help choose safer statin alternatives or lower dosages to minimize toxicity¹⁶.

6. HLA Alleles (Human Leukocyte Antigens)

· HLA-B*57:01: Associated with hypersensitivity reactions to abacavir, an antiretroviral used in HIV treatment.

· HLA-B*15:02: Strongly linked to Stevens-Johnson syndrome and toxic epidermal necrolysis in response to carbamazepine, particularly in Southeast Asian populations.

· Clinical Recommendation: Pre-treatment genetic testing for these HLA alleles is now standard practice to avoid severe immune-mediated drug reactions.

Understanding and integrating pharmacogenes into clinical decision-making represents a crucial advancement in precision medicine. The identification of gene-drug interactions enables physicians to optimize treatment plans, avoid adverse effects, and improve therapeutic outcomes based on a patient's unique genetic profile¹⁷.

Role of Pharmacogenomics in Personalized Treatment:

Drug Selection and Dosage Optimization:

Pharmacogenomics enables clinicians to optimize drug selection and dosing by identifying genetic variants that influence drug metabolism and efficacy. Enzymes such as CYP2D6, CYP2C19, and TPMT show variable activity across individuals, classifying them into poor, intermediate, extensive, or ultra-rapid metabolizers. Tailoring therapy according to these genetic categories can prevent toxicity and improve drug efficacy¹⁸.

Table 01 Role of Pharmacogenomics in Personalized Treatment

Gene	Drug(s)	Impact of Genetic Variation	Clinical Action
CYP2D6	Codeine, Tramadol	PMs may not activate codeine; UMs risk toxicity	Use alternatives or adjust dose
CYP2C19	Clopidogrel	PMs have reduced efficacy	Use prasugrel or ticagrelor
CYP2C9/VKORC1	Warfarin	Increased bleeding risk	Initiate at reduced dose
TPMT	Azathioprine, 6-MP	Risk of bone marrow suppression	Reduce dose or choose alternative
DPYD	5-FU, Capecitabine	Risk of life-threatening toxicity	Avoid or reduce dose

Prevention of Adverse Drug Reactions (ADRs):

Pharmacogenomic testing can prevent ADRs by identifying individuals at risk for drug toxicity or hypersensitivity. For example, the HLA-B57:01 allele predicts abacavir hypersensitivity, while HLA-B15:02 is linked to carbamazepine-induced Stevens-Johnson syndrome¹⁹.

Table 02 Prevention of Adverse Drug Reactions

Gene/Allele	Drug	ADR	At-Risk Population
HLA-B*57:01	Abacavir	Hypersensitivity	European ancestry
HLA-B*15:02	Carbamazepine	SJS/TEN	Southeast Asians
TPMT	Azathioprine	Bone marrow suppression	Global
DPYD	5-FU	Severe toxicity	Global
SLCO1B1	Simvastatin	Myopathy	Europeans higher risk
CYP2C9/VKORC1	Warfarin	Bleeding	Global

Enhanced Therapeutic Efficacy:

Pharmacogenomics can enhance drug efficacy by ensuring the right drug reaches the right target in genetically suitable patients. Prodrugs such as clopidogrel and tamoxifen require activation by enzymes like CYP2C19 and CYP2D6, respectively. Patients with reduced function alleles may not benefit from these treatments²⁰.

Table 03 Enhancement of Therapeutic Efficacy

Drug	Gene/Target	Application	Insight
Clopidogrel	CYP2C19	Antiplatelet therapy	Reduced activation in PMs
Gefitinib, Erlotinib	EGFR	Lung cancer	High response in EGFR-mutant NSCLC
Imatinib	BCR-ABL	CML	Targets mutated kinase
Trastuzumab	HER2	Breast cancer	Works in HER2+ tumors
Tamoxifen	CYP2D6	Breast cancer	Poor metabolizers show lower efficacy

Development of Targeted Therapies:

Pharmacogenomic insights have facilitated the development of targeted therapies for genetically defined patient subsets. These drugs are more precise and effective and often come with companion diagnostics²¹.

Table 04 Development of Targeted Therapies

Drug	Target	Disease	Mechanism
Trastuzumab	HER2	HER2+ Breast Cancer	HER2 receptor inhibition
Imatinib	BCR-ABL	CML	Tyrosine kinase inhibitor
Erlotinib	EGFR	NSCLC	EGFR tyrosine kinase inhibition
Vemurafenib	BRAF V600E	Melanoma	BRAF inhibitor
Ivacaftor	CFTR G551D	Cystic Fibrosis	CFTR potentiation

Tailored Treatment in Chronic Diseases:

Pharmacogenomics supports chronic disease management by guiding long-term drug therapy. It helps avoid ineffective treatments and long-term adverse events²².

Table 05 Treatment of Chronic Diseases

Disease	Genes	Drugs	Benefit
Hypertension	CYP2D6, ADRB1	Beta-blockers	Better response prediction
Depression	CYP2D6, CYP2C19	SSRIs, TCAs	Personalized antidepressant choice
Diabetes	KCNJ11, TCF7L2	Sulfonylureas	Predicts efficacy/failure
Asthma	ADRB2	Beta-agonists	Better responder selection
Epilepsy	SCN1A, HLA	AEDs	Reduces toxicity, improves seizure control

Clinical Implementation and Challenges:

Despite the growing body of scientific evidence supporting pharmacogenomics, its integration into mainstream clinical practice remains challenging. Although the promise of personalized, safer, and more effective drug therapies is widely acknowledged, real-world application is impeded by several practical, technical, economic, and ethical barriers. This section provides an in-depth analysis of the current landscape, implementation strategies, obstacles, and international initiatives aimed at advancing the clinical uptake of pharmacogenomics^23,24.

Current Clinical Applications of Pharmacogenomics:

Pharmacogenomic testing has gained clinical utility in various therapeutic areas, especially where adverse drug reactions can be life-threatening or treatment failure carries significant risk. Regulatory agencies such as the FDA have recognized several pharmacogenomic biomarkers for drug labelling, underscoring their relevance in precision prescribing.

Table 06 Applications of Pharmacogenomics

Drug	Gene Tested	Clinical Use
Abacavir	HLA-B*57:01	Prevents hypersensitivity in HIV therapy
Warfarin	CYP2C9, VKORC1	Guides personalized anticoagulant dosing
Clopidogrel	CYP2C19	Optimizes antiplatelet therapy post-stenting
Azathioprine	TPMT	Avoids bone marrow toxicity in autoimmune and cancer care
5-Fluorouracil	DPYD	Prevents severe chemotherapy toxicity
Carbamazepine	HLA-B*15:02	Prevents severe cutaneous adverse reactions in Asian populations

These examples highlight how pharmacogenomics improves safety, efficacy, and cost-effectiveness by enabling clinicians to anticipate drug response and avoid harmful outcomes^25,26.

Implementation Strategies:

Successfully incorporating pharmacogenomics into healthcare systems requires a coordinated approach that spans technology integration, clinical support, and workforce development^27,28.

1. Clinical Decision Support (CDS) Systems:

Integrating pharmacogenomic data into electronic health records (EHRs) with real-time CDS tools allows healthcare providers to receive actionable alerts and recommendations based on a patient’s genetic profile. This facilitates appropriate drug selection and dosing²⁹.

2. Preemptive and Panel-Based Testing:

Rather than testing for a single gene at the time of prescription, preemptive genotyping and use of multi-gene panels provide comprehensive insights that are readily available when needed, reducing delays and supporting point-of-care decisions³⁰.

3. Healthcare Professional Education:

Broad pharmacogenomics literacy is essential. Training programs and updated medical curricula for physicians, pharmacists, and nurses are crucial to ensure understanding of pharmacogenomic data interpretation and its clinical relevance³¹.

Challenges in Clinical Practice:

Despite clear clinical value, implementation is slowed by multiple barriers:

1. Limited Clinical Guidelines and Evidence Gaps:

While organizations like CPIC and DPWG offer practice guidelines, many gene-drug pairs lack sufficient evidence to support routine clinical use. Continuous investment in pharmacogenomics research is needed to validate biomarkers and dosing algorithms³²

2. Cost and Reimbursement Issues:

The high upfront cost of genetic testing and inconsistent insurance coverage pose major financial challenges. Demonstrating long-term cost-effectiveness through pharmacoeconomic studies is key to broader payer acceptance³³.

3. Ethical, Legal, and Social Considerations (ELSI):

Concerns around genetic data privacy, discrimination, and informed consent remain significant. Robust policies are needed to safeguard patients’ genetic information and ensure equitable access to testing and therapies³⁴.

4. Population Diversity and Generalizability:

Most genomic studies are based on populations of European descent, limiting the applicability of findings to other ethnic groups. Enhancing diversity in genomic databases is essential for inclusive and accurate pharmacogenomic practice³⁵.

5. Testing Turnaround and Laboratory Standards:

Delayed or inconsistent test results can impede clinical decision-making. Standardization of testing protocols and ensuring rapid, high-quality laboratory processing is necessary to support timely interventions³⁶.

Global and Institutional Initiatives:

Multiple international and institutional efforts are driving the adoption of pharmacogenomics:

· The Clinical Pharmacogenetic Implementation Consortium (CPIC) and PharmGKB provide curated, evidence-based guidelines and educational resources for clinicians worldwide.

· Institutions like St. Jude Children’s Research Hospital, Mayo Clinic, and Vanderbilt University have established comprehensive pharmacogenomics programs integrated within their clinical systems.

· Global consortia, such as U-PGx (Europe) and IGNITE (USA), promote multicentre collaboration and real-world implementation through pilot programs and shared infrastructure.

These initiatives are helping to translate pharmacogenomic discoveries into tangible clinical benefits and serve as models for other healthcare systems aiming to embrace precision medicine.

The clinical implementation of pharmacogenomics is an on-going journey that demands interdisciplinary collaboration, supportive policy frameworks, and continued investment in research and education. By addressing current limitations and leveraging global initiatives, healthcare systems can unlock the full potential of pharmacogenomics delivering safer, more effective, and individualized therapies for patients across the globe^37,38,39.

Future Perspectives:

Pharmacogenomics continues to evolve at a rapid pace, offering exciting opportunities to reshape the landscape of healthcare and fulfil the promise of precision medicine. As scientific understanding deepens and technological innovations advance, the widespread integration of pharmacogenomics into routine clinical practice is becoming increasingly feasible, cost-effective, and impactful. Several key developments are anticipated to drive the future of this field. ^40,41.

Expansion of Pharmacogenomic Testing:

· From single-gene to multi-gene panels:

The future will shift from limited single-gene testing to the adoption of comprehensive pharmacogenomic panels or even whole-exome/genome sequencing. This broader approach enables preemptive profiling that can be leveraged throughout a patient’s lifetime for multiple therapeutic decisions^42,43,44.

· Point-of-care testing:

Innovations in rapid, bedside genetic testing technologies will enable clinicians to access real-time genetic insights. This will be particularly valuable in acute and emergency care settings, where timely treatment decisions are critical⁴⁵.

Integration with Digital Health and Artificial Intelligence (AI)

· AI and machine learning:

Advanced computational tools will enable the integration of vast genetic, phenotypic, and environmental datasets to predict individual drug responses with high precision.

· Clinical Decision Support Systems (CDSS):

Seamless integration of pharmacogenomic data with electronic health records (EHRs) will allow automated, evidence-based prescribing support tailored to a patient’s genetic profile, enhancing clinical decision-making^46,47,48.

Greater Inclusion of Diverse Populations:

· Current pharmacogenomic research predominantly reflects populations of European ancestry, limiting generalizability.

· Future initiatives will prioritize the inclusion of genetically diverse populations to improve the global relevance and equity of pharmacogenomic-guided care.

· Expansion of bio banks and global genomic databases such as UK Bio bank and All of Us will enhance representation and help identify population-specific pharmacogenomic markers^49,50.

Personalized Drug Development and Clinical Trials:

· Genotype-stratified clinical trials:

Pharmacogenomic data will increasingly guide patient stratification in clinical trials, enabling more targeted and efficient drug development.

· Improved success rates:

Tailoring study cohorts to genetically defined responders will increase drug efficacy and reduce trial failure rates.

· Genotype-specific drug labelling:

Future drug labels may routinely include genomic markers to guide prescribing decisions, enhancing clinical utility^51,52.

Policy, Ethical, and Regulatory Advancements:

· Future policies will address key issues surrounding the ethical collection, storage, and use of genetic data.

· Regulatory oversight will be essential for ensuring transparency, informed consent, and the safe use of direct-to-consumer genetic tests.

· International standards and harmonized protocols for testing, data analysis, and clinical reporting will facilitate global implementation.

· Governments and insurers are expected to support pharmacogenomic testing through funding, reimbursement policies, and public health initiatives^53,54.

Patient Empowerment and Education:

· Empowered patients will increasingly use genetic information to engage in shared decision-making with clinicians.

· Education campaigns will be vital to build public trust and understanding of pharmacogenomic testing, its benefits, and limitations.

· Tools and resources tailored for non-specialist audiences will support genetic literacy and informed healthcare choices.

The future of pharmacogenomics is one of promise and progress. By overcoming existing challenges and embracing innovation, pharmacogenomics is set to become a cornerstone of predictive, preventive, personalized, and participatory (P4) medicine. With sustained efforts in research, policy development, and education, the field will continue to deliver safer, more effective, and equitable healthcare solutions for populations around the world^55,56.

CONCLUSION:

The integration of pharmacogenomics into modern healthcare marks a pivotal step toward achieving the vision of personalized medicine. By elucidating the genetic basis of interindividual variability in drug response, pharmacogenomics provides critical insights into optimizing drug selection, dosing, and safety. This individualized approach enables clinicians to move beyond the limitations of the traditional “one-size-fits-all” paradigm and toward therapies that are precisely tailored to a patient’s genetic profile. This review has outlined the essential roles of genetic polymorphisms and pharmacogenes in influencing pharmacokinetics and pharmacodynamics. It has also highlighted key clinical applications, including prevention of adverse drug reactions, enhancement of therapeutic efficacy, and the development of targeted therapies for both acute and chronic conditions. The clinical implementation of pharmacogenomic-guided therapy has already begun in various healthcare systems, supported by decision-support tools, preemptive testing strategies, and educational initiatives. However, widespread adoption still faces significant challenges ranging from lack of population diversity in genomic data, cost and reimbursement issues, to ethical and regulatory considerations. Bridging these gaps requires coordinated efforts in research, healthcare policy, infrastructure development, and education. Looking forward, the future of pharmacogenomics is promising. The continued evolution of genomic technologies, integration with artificial intelligence and digital health platforms, expansion of diverse genomic datasets, and active patient engagement will be key drivers of progress. As pharmacogenomics becomes more embedded in clinical workflows, it holds the transformative potential to make medicine not only more precise and effective but also more equitable and sustainable.

REFERENCES:

1. Mathur S, Sutton J. Personalized medicine could transform healthcare. Biomed Rep. 2017; 7(1):3-5.

2. Sadee W, Wang D, Hartmann K, Toland AE. Pharmacogenomics: driving personalized medicine. Pharmacol Rev. 2023; 75(4):789-814.

3. Swapnaa B, Santhosh Kumar V. Personalized Medicine - A Novel approach in Cancer Therapy. Research J. Pharm. and Tech. 2017; 10(1): 341-345.

4. Madian AG, Wheeler HE, Jones RB, Dolan ME. Relating human genetic variation to variation in drug responses. Trends Genet. 2012; 28(10):487-95.

5. Armila Sen, Komal Kumar, Shaheen Khan, Priyanka Pathak, Arjun Singh. Current Therapy in Cancer: Advances, Challenges, and Future Directions. Asian Journal of Nursing Education and Research. 2024; 14(1):77-4.

6. Robert J, Le Morvan V, Smith D, Pourquier P, Bonnet J. Predicting drug response and toxicity based on gene polymorphisms. Crit Rev Oncol Hematol. 2005; 54(3):171-96.

7. He Y, Hoskins JM, McLeod HL. Copy number variants in pharmacogenetic genes. Trends Mol Med. 2011; 17(5):244-51.

8. Isvoran A, Louet M, Vladoiu DL, Craciun D, Loriot MA, Villoutreix BO, et al. Pharmacogenomics of the cytochrome P450 2C family: impacts of amino acid variations on drug metabolism. Drug Discov Today. 2017; 22(2):366-76.

9. Wolking S, Schaeffeler E, Lerche H, Schwab M, Nies AT. Impact of genetic polymorphisms of ABCB1 (MDR1, P-glycoprotein) on drug disposition and potential clinical implications: update of the literature. Clin Pharmacokinet. 2015; 54:709-35.

10. Sahil Mahajan, Heemani Dave, Santosh Bothe, Debarshikar Mahpatra, Sandeep Sonawane, Sanjay Kshirsagar, Santosh Chhajed. Objective Monitoring of Cardiovascular Biomarkers using Artificial Intelligence (AI). Asian Journal of Pharmaceutical Research. 2022; 12(3):229-4.

11. Katara P, Yadav A. Pharmacogenes (PGx-genes): current understanding and future directions. Gene. 2019; 718:144050.

12. Sangeet Kumar Mall, Priti Dipa, Shambaditya Goswami, Prashant Singh, Ravindra Pal Singh. Pharmacovigilance programme in India (PvPI): History, Current scenario, future aspects and role in COVID 19. Asian Journal of Research in Pharmaceutical Sciences. 2022; 12(3):205-9.

13. Yukta Ajaykumar Patel, Kantilal Narkhede, Anuradha Prajapati, Sachin Narkhede, Shailesh Luhar. Asian Journal of Pharmacy and Technology. 2025; 15(1):51-6.

14. Gharge Deepali, Bavaskar Sunil, Todkar Pavan,Dhabale Pandurang. Pharmacogenomics: An Overview. Research J. Pharmacology and Pharmacodynamics. 2009; 1(2): 59-65.

15. Zhou S, Brink. Clinical pharmacogenomics of thiopurine S-methyltransferase. Curr Clin Pharmacol. 2006; 1(1):119-28.

16. Lin R, Wang X, Zhou W, Fu W, Wang Y, Huang W, et al. Association of polymorphisms in the solute carrier organic anion transporter family member 1B1 gene with essential hypertension in the Uyghur population. Ann Hum Genet. 2011; 75(2):305-11.

17. Williams TM. Human leukocyte antigen gene polymorphism and the histocompatibility laboratory. J Mol Diagn. 2001; 3(3):98-104.

18. Roman YM. Pharmacogenomics and rare diseases: optimizing drug development and personalized therapeutics. Pharmacogenomics. 2025; :1-8.

19. Micaglio E, Locati ET, Monasky MM, Romani F, Heilbron F, Pappone C. Role of pharmacogenetics in adverse drug reactions: an update towards personalized medicine. Front Pharmacol. 2021; 12:651720.

20. Pirmohamed M. Personalized pharmacogenomics: predicting efficacy and adverse drug reactions. Annu Rev Genomics Hum Genet. 2014; 15:349-70.

21. Seebacher NA, Stacy AE, Porter GM, Merlot AM. Clinical development of targeted and immune based anti-cancer therapies. J Exp Clin Cancer Res. 2019; 38(1):156.

22. Wensing M, Oxman A, Baker R, Godycki-Cwirko M, Flottorp S, Szecsenyi J, et al. Tailored implementation for chronic diseases (TICD): a project protocol. Implement Sci. 2011; 6:1-8.

23. P. V. Kamala Kumari, Y. Srinivasa Rao. Personalized Medicine- A Review. Research J. Pharm. and Tech 2019; 12(8):3989-3992.

24. Qahwaji R, Ashankyty I, Sannan NS, Hazzazi MS, Basabrain AA, Mobashir M. Pharmacogenomics: a genetic approach to drug development and therapy. Pharmaceuticals. 2024; 17(7):940.

25. Ma JD, Lee KC, Kuo GM. Clinical application of pharmacogenomics. J Pharm Pract. 2012; 25(4):417-27.

26. Adamu Yau, Nordin Bin Simbak, Mainul Haque. Pharmacogenovigilance: A Potential Tool in Pharmacovigilance. Research J. Pharm. and Tech. 7(12): Dec. 2014; Page 1476-1482.

27. van der Wouden CH, Cambon-Thomsen A, Cecchin E, Cheung KC, Dávila-Fajardo CL, Deneer VH, et al. Implementing pharmacogenomics in Europe: design and implementation strategy of the ubiquitous pharmacogenomics consortium. Clin Pharmacol Ther. 2017; 101(3):341-58.

28. Klein ME, Parvez MM, Shin JG. Clinical implementation of pharmacogenomics for personalized precision medicine: barriers and solutions. J Pharm Sci. 2017; 106(9):2368-79.

29. Wake DT, Smith DM, Kazi S, Dunnenberger HM. Pharmacogenomic clinical decision support: a review, how-to guide, and future vision. Clin Pharmacol Ther. 2022; 112(1):44-57.

30. Rayees N M, Sampath Kumar, Bharath Raj K C, Rajesh K S, Juno J Joel, Prasanna Shama K, Gururaja M P, Nandakumar U P. A Prospective Observational Study on Adverse Drug Reactions in General Medicine Department of a Tertiary Care Teaching Hospital. Research J. Pharm. and Tech. 2019; 12(5):2289-2298.

31. Omran S, Leong SL, Blebil A, Mohan D, Teoh SL. Effectiveness of pharmacogenomics educational interventions on healthcare professionals and health professions students: a systematic review. Res Social Adm Pharm. 2023; 19(11):1399-411.

32. Hippman C, Nislow C. Pharmacogenomic testing: clinical evidence and implementation challenges. J Pers Med. 2019; 9(3):40.

33. Cohen J, Wilson A, Manzolillo K. Clinical and economic challenges facing pharmacogenomics. Pharmacogenomics J. 2013; 13(4):378-88.

34. Rudschies C, Schneider I. Ethical, legal, and social implications (ELSI) of virtual agents and virtual reality in healthcare. Soc Sci Med. 2024; 340:116483.

35. Ji X, Ning B, Liu J, Roberts R, Lesko L, Tong W, et al. Towards population-specific pharmacogenomics in the era of next-generation sequencing. Drug Discov Today. 2021; 26(8):1776-83.

36. Moyer AM, Black JL. Pharmacogenomic testing in the clinical laboratory: historical progress and future opportunities. Ann Lab Med. 2025; 45(3):247-58.

37. Cavallari LH, Hicks JK, Patel JN, Elchynski AL, Smith DM, Bargal SA, et al. The Pharmacogenomics Global Research Network Implementation Working Group: global collaboration to advance pharmacogenetic implementation. Pharmacogenet Genomics. 2025; 35(1):1-11.

38. Relling MV, Klein TE. CPIC: clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin Pharmacol Ther. 2011; 89(3):464-7.

39. Alshabeeb MA, Alyabsi M, Aziz MA, Abohelaika S. Pharmacogenes that demonstrate high association evidence according to CPIC, DPWG, and PharmGKB. Front Med. 2022; 9:1001876.

40. Pirmohamed M. Pharmacogenomics: current status and future perspectives. Nat Rev Genet. 2023; 24(6):350-62.

41. Ishikawa T, Ware J. Future perspectives. Pharmacogenomics of human drug transporters: clinical impacts. 2013; :401-16.

42. Rothschild AJ, Parikh SV, Hain D, Law R, Thase ME, Dunlop BW, et al. Clinical validation of combinatorial pharmacogenomic testing and single-gene guidelines in predicting psychotropic medication blood levels and clinical outcomes in patients with depression. Psychiatry Res. 2021; 296:113649.

43. Lu CY, Loomer S, Ceccarelli R, Mazor KM, Sabin J, Clayton EW, et al. Insurance coverage policies for pharmacogenomic and multi-gene testing for cancer. J Pers Med. 2018; 8(2):19.

44. Scott SA. Clinical pharmacogenomics: opportunities and challenges at point of care. Clin Pharmacol Ther. 2013; 93(1):33-5.

45. Solaiman M, Tisha SJ, Dawood M. Artificial intelligence in the field of pharmacogenomics. Int J Eng Technol Res Manag. 2025; 9(04).

46. Lin E, Lin CH, Lane HY. Precision psychiatry applications with pharmacogenomics: artificial intelligence and machine learning approaches. Int J Mol Sci. 2020; 21(3):969.

47. Smith DM, Wake DT, Dunnenberger HM. Pharmacogenomic clinical decision support: a scoping review. Clin Pharmacol Ther. 2023; 113(4):803-15.

48. Popejoy AB. Diversity in precision medicine and pharmacogenetics: methodological and conceptual considerations for broadening participation. Pharmacogenomics Pers Med. 2019; :257-71.

49. Zhang H, De T, Zhong Y, Perera MA. The advantages and challenges of diversity in pharmacogenomics: can minority populations bring us closer to implementation? Clin Pharmacol Ther. 2019; 106(2):338-49.

50. Mirsadeghi S, Larijani B. Personalized medicine: pharmacogenomics and drug development. Acta Med Iran. 2017; :150-65.

51. Limaye N. Pharmacogenomics, theranostics and personalized medicine-the complexities of clinical trials: challenges in the developing world. Appl Transl Genom. 2013; 2:17-21.

52. Peterson-Iyer K. Pharmacogenomics, ethics, and public policy. Kennedy Inst Ethics J. 2008; 18(1):35-56.

53. Paul NW, Roses AD. Pharmacogenetics and pharmacogenomics: recent developments, their clinical relevance and some ethical, social, and legal implications. J Mol Med. 2003; 81:135-40.

54. Alanazi DHK, Alanazi AHK, Alanazi SAK, Alanazi BFA, Alfaqeer AA, Aljohani FS, et al. Pharmacogenomics: implications for nursing and pharmacy collaboration in personalized medicine. J Int Crisis Risk Commun Res. 2024; 7(S11).

55. Mukund M. Pache, Rutuja R. Pangavhane, Siddhi V. Nikam, Ramdas B. Rode, Avinash B. Darekar. CRISPR-Cas9 in Pharmaceutical Research: Applications, Challenges, Ethical Considerations and Future Directions. Asian Journal of Pharmacy and Technology. 2025; 15(3):296-4.

Received on 23.07.2025 Revised on 15.09.2025

Accepted on 28.10.2025 Published on 20.01.2026

Available online from January 27, 2026

Asian J. Pharm. Tech. 2026; 16(1):91-98.

DOI: 10.52711/2231-5713.2026.00013

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License.